Say good­bye to plants: Syn­bio play­er An­theia earns new back­ers in quest to re­design flo­ra-de­rived med­i­cine man­u­fac­tur­ing

The age of syn­thet­ic bi­ol­o­gy is of­fi­cial­ly up­on us with su­per-uni­corns like Gink­go Bioworks chang­ing the game in terms of how in­vestors view those cell en­gi­neer­ing plat­forms. Now, a Cal­i­for­nia com­pa­ny look­ing to do away with frag­ile flo­ra sup­ply chains in drug de­vel­op­ment has earned a new round of in­vest­ment to chase its goal.

Syn­bio play­er An­theia raised a $73 mil­lion Se­ries B round it will use to ad­vance its pipeline of com­pounds de­rived from a plant-al­ter­na­tive man­u­fac­tur­ing process us­ing whole yeast cell en­gi­neer­ing, the com­pa­ny said Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER